SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001213900-22-076318
Filing Date
2022-11-30
Accepted
2022-11-30 14:41:35
Documents
2
Period of Report
2022-11-30

Document Format Files

Seq Description Document Type Size
1 REPORT OF FOREIGN PRIVATE ISSUER ea169475-6k_biondvaxpharma.htm 6-K 18331
2 PRESS RELEASE DATED NOVEMBER 30, 2022 ea169475ex99-1_biondvax.htm EX-99.1 105991
  Complete submission text file 0001213900-22-076318.txt   125417
Mailing Address JERUSALEM BIOPARK, 2ND FLOOR HADASSAH EIN KEREM CAMPUS JERUSALEM L3 00000
Business Address JERUSALEM BIOPARK, 2ND FLOOR HADASSAH EIN KEREM CAMPUS JERUSALEM L3 00000 972-8-9302529
BiondVax Pharmaceuticals Ltd. (Filer) CIK: 0001611747 (see all company filings)

IRS No.: 000000000 | State of Incorp.: L3 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-37353 | Film No.: 221435286
SIC: 2836 Biological Products, (No Diagnostic Substances)